Skip to main content
SpringerLink
Log in

Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

  • Chapter
  • First Online:
Plasma Cell Dyscrasias

Part of the book series: Cancer Treatment and Research ((CTAR,volume 169))

Abstract

Treatment approaches for newly diagnosed myeloma have changed considerably during the past decade, along with a better understanding of the disease heterogeneity. Availability of new drug classes such as proteasome inhibitors and immunomodulatory drugs, and use of these drugs in combinations have led to higher response rates and deeper responses in the vast majority of patients with newly diagnosed myeloma. In addition to improved efficacy, these regimens are tolerated better than those with conventional chemotherapy drugs, which have reduced the early mortality seen in MM, while allowing for successful stem cell collection in patients undergoing stem cell transplant consolidation. Ongoing clinical trials with newer drugs such as monoclonal antibodies are being explored as options for newly diagnosed MM. The optimal regimen continues to evolve and is often dictated by the intent to transplant, age and comorbidities. Despite the increasing response rates seen with the new regimens, autologous stem cell transplantation remains an effective modality for consolidation, further deepening the responses seen with the initial therapy. Post-transplant approaches have further added to the efficacy of this platform with both post-transplant consolidation and maintenance demonstrating value in clinical trials. Currently, the combination of an effective initial therapy followed by one or two autologous stem cell transplants, with or without consolidation followed by maintenance appear to provide the maximum benefit in terms of duration of disease control for patients with newly diagnosed MM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 84.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Avet-Loiseau H (2007) Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 20(4):625–635

    Article  CAS  PubMed  Google Scholar 

  2. Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420

    Article  PubMed  Google Scholar 

  3. Munshi NC, Anderson KC, Bergsagel PL et al (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18):4696–4700

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Boyd KD, Ross FM, Chiecchio L et al (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26(2):349–355

    Article  CAS  PubMed  Google Scholar 

  5. Zhan F, Hardin J, Kordsmeier B et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745–1757

    Article  CAS  PubMed  Google Scholar 

  6. Decaux O, Lode L, Magrangeas F et al (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 26(29):4798–4805

    Article  CAS  PubMed  Google Scholar 

  7. Rajkumar SV, Rosinol L, Hussein M et al (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26(13):2171–2177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kumar S, Dispenzieri A, Lacy MQ et al (2007) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21(9):2035–2042

    Article  CAS  PubMed  Google Scholar 

  9. Paripati H, Stewart AK, Cabou S et al (2008) Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 22(6):1282–1284

    Article  CAS  PubMed  Google Scholar 

  10. Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142(10):1298–1302

    Article  CAS  PubMed  Google Scholar 

  11. Harousseau JL, Attal M, Avet-Loiseau H et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28(30):4621–4629

    Article  CAS  PubMed  Google Scholar 

  12. Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440

    Article  PubMed  Google Scholar 

  13. Mitsiades N, Mitsiades CS, Richardson PG et al (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101(6):2377–2380

    Article  CAS  PubMed  Google Scholar 

  14. Reeder CB, Reece DE, Kukreti V et al (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23(7):1337–1341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cavo M, Tacchetti P, Patriarca F et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376(9758):2075–2085

    Article  CAS  PubMed  Google Scholar 

  16. Rosinol L, Oriol A, Teruel AI et al (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120(8):1589–1596

    Article  CAS  PubMed  Google Scholar 

  17. Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679–686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jakubowiak AJ, Dytfeld D, Griffith KA et al (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120(9):1801–1809

    Article  CAS  PubMed  Google Scholar 

  19. Korde N, Roschewski M, Zingone A et al (2015) Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 1(6):746–754

    Article  PubMed  Google Scholar 

  20. Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955

    Article  CAS  PubMed  Google Scholar 

  21. Kumar S, Flinn I, Richardson PG et al (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119(19):4375–4382

    Article  CAS  PubMed  Google Scholar 

  22. Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109(6):2604–2606

    Article  CAS  PubMed  Google Scholar 

  23. Badros AZ, Vij R, Martin T et al (2013) Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 27(8):1707–1714

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Laura R, Cibeira MT, Uriburu C et al (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76(5):405–408

    Article  PubMed  Google Scholar 

  25. Hughes M, Micallef-Eynaud P (2006) Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas. Clin Lab Haematol 28(4):267–269

    Article  CAS  PubMed  Google Scholar 

  26. Ali R, Ozkalemkas F, Ozkan A et al (2007) Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Leuk Res 31(8):1153–1155

    Article  CAS  PubMed  Google Scholar 

  27. D’Arena G, Valentini CG, Pietrantuono G et al (2012) Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 23(6):1499–1502

    Article  PubMed  Google Scholar 

  28. Libby E, Candelaria-Quintana D, Moualla H, Abdul-Jaleel M, Rabinowitz I (2010) Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol 85(9):733–734

    Article  PubMed  Google Scholar 

  29. Al-Nawakil C, Tamburini J, Bardet V et al (2008) Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 49(10):2012–2014

    Article  CAS  PubMed  Google Scholar 

  30. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91–97

    Article  CAS  PubMed  Google Scholar 

  31. Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875–1883

    Article  CAS  PubMed  Google Scholar 

  32. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431–436

    Article  CAS  PubMed  Google Scholar 

  33. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487–2498

    Article  CAS  PubMed  Google Scholar 

  34. Rajkumar SV, Jacobus S, Callander N et al (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 110(11):74

    Google Scholar 

  35. Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Palumbo A, Bringhen S, Petrucci MT et al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104(10):3052–3057

    Article  CAS  PubMed  Google Scholar 

  37. Fermand JP, Katsahian S, Divine M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23(36):9227–9233

    Article  CAS  PubMed  Google Scholar 

  38. Barlogie B, Kyle RA, Anderson KC et al (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24(6):929–936

    Article  CAS  PubMed  Google Scholar 

  39. Blade J, Rosinol L, Sureda A et al (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106(12):3755–3759

    Article  CAS  PubMed  Google Scholar 

  40. Fermand JP, Ravaud P, Chevret S et al (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9):3131–3136

    CAS  PubMed  Google Scholar 

  41. Palumbo A, Cavallo F, Gay F et al (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895–905

    Article  PubMed  Google Scholar 

  42. Moreau P, Facon T, Attal M et al (2002) Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 99(3):731–735

    Article  CAS  PubMed  Google Scholar 

  43. Siegel DS, Desikan KR, Mehta J et al (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93(1):51–54

    CAS  PubMed  Google Scholar 

  44. Kumar SK, Dingli D, Lacy MQ et al (2008) Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 83(8):614–617

    Article  PubMed  Google Scholar 

  45. Gertz MA, Lacy MQ, Dispenzieri A et al (2007) Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 39(10):605–611

    Article  CAS  PubMed  Google Scholar 

  46. Kumar S, Lacy MQ, Dispenzieri A et al (2004) High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 34(2):161–167

    Article  CAS  PubMed  Google Scholar 

  47. Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26):2495–2502

    Article  CAS  PubMed  Google Scholar 

  48. Cavo M, Tosi P, Zamagni E et al (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25(17):2434–2441

    Article  PubMed  Google Scholar 

  49. Sonneveld P, van der Holt B, Vellenga E et al (2005) Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Final Analysis of the HOVON 24 Trial. Blood 106(11):2545

    Google Scholar 

  50. JP F, C A, JP M. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Hematol J. 2003;4(Suupl 1):S59

    Google Scholar 

  51. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B (2009) Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 101(2):100–106

    Article  CAS  PubMed  Google Scholar 

  52. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B (1995) Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 16(1):7–11

    CAS  PubMed  Google Scholar 

  53. Elice F, Raimondi R, Tosetto A et al (2006) Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 81(6):426–431

    Article  PubMed  Google Scholar 

  54. Morris C, Iacobelli S, Brand R et al (2004) Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 22(9):1674–1681

    Article  CAS  PubMed  Google Scholar 

  55. Alexanian R, Balcerzak S, Bonnet JD et al (1975) Prognostic factors in multiple myeloma. Cancer 36(4):1192–1201

    Article  CAS  PubMed  Google Scholar 

  56. Treatment comparisons in the third MRC myelomatosis trial (1980) Medical research council’s working party on leukaemia in adults. Br J Cancer 42(6):823–830

    Article  Google Scholar 

  57. Cohen HJ, Bartolucci AA, Forman WB, Silberman HR (1986) Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. J Clin Oncol 4(6):888–899

    CAS  PubMed  Google Scholar 

  58. Belch A, Shelley W, Bergsagel D et al (1988) A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 57(1):94–99

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Berenson JR, Crowley JJ, Grogan TM et al (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99(9):3163–3168

    Article  CAS  PubMed  Google Scholar 

  60. Shustik C, Belch A, Robinson S et al (2007) A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 136(2):203–211

    Article  CAS  PubMed  Google Scholar 

  61. Mellstedt H, Aahre A, Bjorkholm M et al (1979) Interferon therapy in myelomatosis. Lancet 2(8144):697

    CAS  PubMed  Google Scholar 

  62. Fritz E, Ludwig H (2000) Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11(11):1427–1436

    Article  CAS  PubMed  Google Scholar 

  63. Interferon as therapy for multiple myeloma (2001) an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113(4):1020–1034

    Article  Google Scholar 

  64. Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21):1565–1571

    Article  CAS  PubMed  Google Scholar 

  65. Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10):3289–3294

    Article  CAS  PubMed  Google Scholar 

  66. Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030

    Article  CAS  PubMed  Google Scholar 

  67. Morgan GJ, Davies FE, Gregory WM et al (2013) Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 19(21):6030–6038

    Article  CAS  PubMed  Google Scholar 

  68. Morgan GJ, Gregory WM, Davies FE et al (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119(1):7–15

    Article  CAS  PubMed  Google Scholar 

  69. Lokhorst HM, van der Holt B, Zweegman S et al (2010) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115(6):1113–1120

    Article  CAS  PubMed  Google Scholar 

  70. Stewart AK, Trudel S, Bahlis NJ et al (2013) A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 121(9):1517–1523

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Spencer A, Prince HM, Roberts AW et al (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27(11):1788–1793

    Article  CAS  PubMed  Google Scholar 

  72. Krishnan A, Pasquini MC, Logan B et al (2011) Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 12(13):1195–1203

    Article  PubMed  PubMed Central  Google Scholar 

  73. Maiolino A, Hungria VT, Garnica M et al (2012) Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 87(10):948–952

    Article  CAS  PubMed  Google Scholar 

  74. Kagoya Y, Nannya Y, Kurokawa M (2012) Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res 36(8):1016–1021

    Article  CAS  PubMed  Google Scholar 

  75. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609–2617

    Article  CAS  PubMed  Google Scholar 

  76. Attal M, Lauwers-Cances V, Marit G et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782–1791

    Article  CAS  PubMed  Google Scholar 

  77. Attal M, Lauwers-Cances V, Marit G et al (2013) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial. Blood 122(21):406

    Google Scholar 

  78. McCarthy PL, Owzar K, Hofmeister CC et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770–1781

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. McCarthy P, Owzar K, Hofmeister CC et al (2013) Analysis of overall survival (OS) in the context of cross-over from placebo to lenalidomide and the incidence of second primary alignancies (SPM) in the phase III study of lenalidomide versus placebo maintenance therapy following autologous stem cell transplant (ASCT) for multiple myeloma (MM) CALGB (Alliance) ECOG BMTCTN. Clin Lymphoma Myeloma Leuk 13(Suppl 1):S28

    Google Scholar 

  80. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B (1996) Graft-versus-myeloma effect: proof of principle. Blood 87(3):1196–1198

    CAS  PubMed  Google Scholar 

  81. Garban F, Attal M, Michallet M et al (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107(9):3474–3480

    Article  CAS  PubMed  Google Scholar 

  82. Bruno B, Rotta M, Patriarca F et al (2007) A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356(11):1110–1120

    Article  CAS  PubMed  Google Scholar 

  83. Barlogie B, Jagannath S, Vesole DH et al (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89(3):789–793

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, Boston, MA, USA

    Jacob Laubach

  2. Mayo Clinic, Rochester, MN, USA

    Shaji Kumar

Authors
  1. Jacob Laubach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaji Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jacob Laubach or Shaji Kumar .

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncolgy/Hematology,, ASST-Spedali Civili di Brescia Dept. of Medical Oncolgy/Hematology,, Brescia, Brescia, Italy

    Aldo M. Roccaro

  2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

    Irene M. Ghobrial

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Laubach, J., Kumar, S. (2016). Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. In: Roccaro, A., Ghobrial, I. (eds) Plasma Cell Dyscrasias. Cancer Treatment and Research, vol 169. Springer, Cham. https://doi.org/10.1007/978-3-319-40320-5_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40320-5_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40318-2

  • Online ISBN: 978-3-319-40320-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation